A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms

被引：0

作者：

Rambaldi, Alessandro ^{[1
]}

Dellacasa, Chiara Maria ^{[2
]}

Salmoiraghi, Silvia ^{[2
]}

Spinelli, Orietta ^{[2
]}

Ferrari, Maria Luisa ^{[2
]}

Gattoni, Elisabetta ^{[3
]}

Guglielmelli, Paola ^{[4
]}

Vannucchi, Alessandro M. ^{[4
]}

Barosi, Giovanni ^{[5
]}

Barbui, Tiziano ^{[2
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Clin Hematol Div, Barcelona, Spain

[2] Osped Riuniti Bergamo, USC Hematol, I-24100 Bergamo, Italy

[3] Policlin San Matteo, Fdn IRCCS, Lab Epidemiol Clin, I-27100 Pavia, Italy

[4] Univ Florence, Florence, Italy

[5] Ist Policlin San Matteo, Clin Epidemiol Unit, Ctr Study Myelofibrosis, Pavia, Italy

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：44 / 45

页数：2

共 50 条

[21] Pleckstrin-2 is a Novel Diagnostic Marker in JAK2V617F Positive Myeloproliferative Neoplasms
Rahimi, Nina
Han, Xu
Gao, Juehua
Ji, Peng
MODERN PATHOLOGY, 2019, 32
[22] Pleckstrin-2 is a Novel Diagnostic Marker in JAK2V617F Positive Myeloproliferative Neoplasms
Rahimi, Nina
Han, Xu
Gao, Juehua
Ji, Peng
LABORATORY INVESTIGATION, 2019, 99
[23] Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloproliferative neoplasms cells
刘贵敏
China Medical Abstracts(Internal Medicine), 2017, 34 (02) : 121 - 121
[24] IN JAK2V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS, BLEEDING RISK CORRELATES WITH ALLELE BURDEN
Bertozzi, I.
Cosi, E.
Santarossa, C.
Bogoni, G.
Fabris, F.
Randi, M. L.
HAEMATOLOGICA, 2017, 102 : 811 - 811
[25] JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
Eickhardt-Dalboge, Christina Schjellerup
Nielsen, Henrik V.
Fuursted, Kurt
Stensvold, Christen Rune
Andersen, Lee O' Brien
Lilje, Berit
Larsen, Morten Kranker
Kjaer, Lasse
Christensen, Sarah Friis
Knudsen, Trine Alma
Skov, Vibe
Sorensen, Anders Lindholm
Ellervik, Christina
Olsen, Lars Ronn
Christensen, Jens Jorgen Elmer
Nielsen, Xiaohui Chen
Hasselbalch, Hans Carl
Ingham, Anna Cacilia
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (05) : 776 - 787
[26] TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Fleischman, Angela G.
Aichberger, Karl J.
Luty, Samuel B.
Bumm, Thomas G.
Petersen, Curtis L.
Doratotaj, Shirin
Vasudevan, Kavin B.
LaTocha, Dorian H.
Yang, Fei
Press, Richard D.
Loriaux, Marc M.
Pahl, Heike L.
Silver, Richard T.
Agarwal, Anupriya
O'Hare, Thomas
Druker, Brian J.
Bagby, Grover C.
Deininger, Michael W.
BLOOD, 2011, 118 (24) : 6392 - 6398
[27] EPIGENETIC CHANGES IN JAK2V617F POSITIVE MYELOPROLIFERATIVE DISORDERS
Uras, A.
Fancello, M. A.
Monne, M.
Piras, G.
Palmas, A. D.
Gaviano, E.
Noli, A.
Bianchi, A.
Gabbas, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 356 - 356
[28] Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms
Ueda, Koki
Ikeda, Kazuhiko
Ikezoe, Takayuki
Harada-Shirado, Kayo
Ogawa, Kazuei
Hashimoto, Yuko
Sano, Takahiro
Ohkawara, Hiroshi
Kimura, Satoshi
Shichishima-Nakamura, Akiko
Nakamura, Yuichi
Shikama, Yayoi
Mori, Tsutomu
Mason, Philip J.
Bessler, Monica
Morishita, Soji
Komatsu, Norio
Shide, Kotaro
Shimoda, Kazuya
Koide, Shuhei
Aoyama, Kazumasa
Oshima, Motohiko
Iwama, Atsushi
Takeishi, Yasuchika
BLOOD ADVANCES, 2017, 1 (15) : 1001 - 1015
[29] How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
Chen, Edwin
Mullally, Ann
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 268 - 276
[30] N-Acetylcysteine As a Therapeutic for JAK2V617F Myeloproliferative Neoplasms
Craver, Brianna
Ramanathan, Gajalakshmi
Luque, Laura Mendez
Hoang, Summer
Elalaoui, Kenza
Brooks, Stefan
Lai, Hew Yeng
Fleischman, Angela
BLOOD, 2018, 132

← 1 2 3 4 5 →